Conversations at the crossroads of science and capital.
Welcome to Clinical Capital Conversations, a podcast and editorial platform hosted by Dr. Peter M. Kovacs, a clinical research pioneer turned global investor.
At the intersection of cutting-edge science and strategic investment, we explore what it really takes to turn medical innovation into scalable impact.
Each episode features unfiltered conversations with:
Clinical research leaders are redefining how trials are run
Biotech and medtech founders building from scratch
Venture capitalists are funding the next generation of health innovation
Policymakers, regulators, and thought leaders shaping the future of medicine
Peter brings his first-hand experience, from founding one of the Worlds most agile clinical trial networks to investing in disruptive health tech startups across Asia and Europe.
This is not another hype podcast. It’s a behind-the-scenes look at how decisions are made, systems are built, and real therapies reach real patients.
Whether you’re a startup founder, scientist, investor, or healthcare strategist, CCC is your front-row seat to the people and ideas moving life sciences forward.
Join Clinical Capital Conversations and be part of the dialogue at the crossroads of science and capital. Get insights, unfiltered stories, and updates on how medical innovation turns into real-world impact, straight to your inbox.
The Last Sense We Lose: Why Voice, Dignity, and Human Connection Will Define the Future of Aging
Dr. Peter M. Kovacs explores aging, loneliness, and ethical AI, arguing that voice technology, dignity, and human connection are essential to preserving identity, legacy, and independence for seniors in a rapidly aging society.
From Chemistry Passion to Clinical Impact: How CROs Must Evolve to Power the Next Generation of Biotech Innovation
Dr. Peter M. Kovacs interviews Jiri Raska of Quinta Analytica on how CROs support biotech startups through biologics, bioequivalence trials, ADC analytics, and Europe’s evolving clinical trial regulations.
The Power of Value: How One MedTech Leader Navigated Transformation, AI Disruption, and the Future of Innovation
A deep look into Jiri Pavlicek’s leadership philosophy revealing how values, courage, and conscious execution shape the future of European MedTech and AI innovation. Why founders who master mindset outperform those who chase technology alone.
Femtech Isn’t a Niche. It’s a Blind Spot. Why I’m Betting on Founders Who Refuse to Be Silenced.
Femtech isn’t a niche; it’s core healthcare. This article explores why rigorous, inclusive innovation in women’s health is overdue, underfunded, and strategically essential. Featuring YON E Health’s clinically validated approach to pH and BBT tracking.
Access to Patients - The Hardest Part of Clinical Research
Patient access is the biggest bottleneck in clinical trials. This article explores why recruitment is so difficult, how databases, referrals, and digital outreach help, and why solving this issue is critical to delivering life-changing treatments faster.
From Budapest to Singapore - A Life-Changing Decision
From Budapest to Singapore, Dr. Peter M. Kovacs shares his bold move to Asia, explains why Singapore became his global hub, and discusses its implications for healthcare, biotech, and investment.
Clinical Research Doesn’t Need More Money, It Needs Better Execution
Clinical research doesn’t need more funding, it needs better execution. Discover a proven operational model that accelerates milestones, improves data quality, and reduces capital waste by 30–50%, offering a strategic edge for institutional co-investors.
A Systematic Approach for De-Risking Biotech and MedTech Investments
Unlock consistent risk-adjusted returns in biotech & MedTech. Learn our systematic approach to de-risking investments by preventing technical execution failures. Our proven methodology, built on 23+ years of experience, reduces capital needs by 30-50% and accelerates milestones, offering a unique opportunity for institutional co-investors.